Alloimmunity in pancreas transplantation

Area of Science:

• Transplantation immunology
• Organ transplantation
• Nephrology

Background:

• Pancreas allograft survival has improved, yet rejection remains a significant clinical challenge.
• Donor-specific antibodies (DSA) and de novo DSA (dnDSA) are increasingly recognized as critical factors in pancreas transplant outcomes.

Purpose of the Study:

• To review emerging literature on the impact of pretransplant and de novo DSA in pancreas transplant recipients.
• To discuss the diagnosis and management of T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) in this patient population.

Main Methods:

• Literature review of recent studies on pancreas transplantation.
• Analysis of diagnostic criteria and treatment strategies for rejection.

Main Results:

• Pretransplant DSA and dnDSA are associated with a higher risk of ABMR.
• Pancreas allograft biopsy is essential for differentiating TCMR and ABMR and guiding therapy.
• Discordant biopsy findings are noted in simultaneous pancreas-kidney transplants.
• Effective treatment of rejection can extend pancreas allograft survival.

Conclusions:

• Accurate and timely diagnosis of alloimmune destruction is paramount for preserving long-term pancreas graft function.
• Physicians require up-to-date information to optimize immunological outcomes in pancreas transplant recipients.